While parenteral prostacyclin (pPCY) therapy, delivered either subcutaneously or intravenously, is recommended for pulmonary arterial hypertension patients with severe or rapidly developing disease, some patients refuse this treatment. This study aimed to understand, directly from patients with pulmonary arterial hypertension, why pPCY was refused and, in some cases, later accepted. Interviews were conducted with 25 pulmonary arterial hypertension patients who previously refused pPCY therapy (Group A: Refused/Never initiated (n = 9) and Group B: Refused/Initiated (n = 16)). Patients in both groups believed that pPCY could improve their symptoms, slow disease progression, and provide them a greater ability to perform activities. Reasons for refusal included concern over side effects and the perceived limitations of pPCY on daily activities. Group A perceived their decision as a balance between quality of life and prolonging life and most acknowledged they would reconsider pPCY if other treatment options were exhausted. Group B cited they initiated therapy due to a worsening of symptoms, disease progression, to improve quality of life, to be there for their family, or a desire to live. Following initiation, Group B indicated their experience met expectations with reduced symptoms, slowed disease progression, and perception of improved survival; concerns related to pPCY were described as manageable. Given the efficacy of pPCY therapy, clinicians should apply knowledge of these findings in clinical practice. Patients noted improvements to parenteral pump technologies to include smaller size, water resistance, and implantability may increase their acceptance of this modality. Development efforts should focus on technologies that increase the acceptance of pPCY when indicated.

1. Simonneau, G, Montani, D, Celermajer, DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53:
Google Scholar | Crossref2. Vazquez, ZGS, Klinger, JR. Guidelines for the treatment of pulmonary arterial hypertension. Lung 2020; 198: 581–596.
Google Scholar | Crossref | Medline3. Galie, N, Humbert, M, Vachiery, JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev Esp Cardiol (English ed) 2016; 69: 177.
Google Scholar | Medline | ISI4. Klinger, JR, Elliott, G, Levine, DJ, et al. Therapy for pulmonary arterial hypertension in adults 2018: update of the chest guideline and expert panel report. Chest 2019; 155: 565–586.
Google Scholar5. Skoro-Sajer, N, Gerges, C, Balint, OH, et al. Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension. Heart (British Cardiac Society) 2018; 104: 1195–1199.
Google Scholar | Crossref | Medline6. Grunig, E, Benjamin, N, Lange, TJ, et al. Safety, tolerability and clinical effects of a rapid dose titration of subcutaneous treprostinil therapy in pulmonary arterial hypertension: a prospective multi-centre trial. Respir Int Rev Thorac Dis 2016; 92: 362–370.
Google Scholar7. Barnes, H, Yeoh, HL, Fothergill, T, et al. Prostacyclin for pulmonary arterial hypertension. Cochrane Database Systematic Rev 2019; 5: Cd012785.
Google Scholar | Medline8. Farber, HW, Miller, DP, Meltzer, LA, et al. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry. J Heart Lung Transplant 2013; 32: 1114–1122.
Google Scholar | Crossref | Medline | ISI9. McLaughlin, VV, Langer, A, Tan, M, et al. Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap. Chest 2013; 143: 324–332.
Google Scholar | Crossref | Medline | ISI10. Hay, BR, Pugh, ME, Robbins, IM, et al. Parenteral prostanoid use at a tertiary referral center: a retrospective cohort study. Chest 2016; 149: 660–666.
Google Scholar | Crossref | Medline11. Mathai, S, Morland, K, Classi, P, et al. Low utilization of prostacyclin therapy prior to death among medicare patients with pulmonary arterial hypertension. Chest 2020; 158: A2164–A2165.
Google Scholar | Crossref12. US Food and Drug Administration. Plan for issuance of patient‐focused drug development guidance. Silver Spring: US Food and Drug Administration, 2017. https://www.fda.gov/files/about%20fda/published/Plan-for-Issuance-of-Patient%E2%80%90Focused-Drug-Development-Guidance.pdf.
Google Scholar13. Doran, AK, Ivy, DD, Barst, RJ, et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008; 160: 5–9.
Google Scholar | Crossref | Medline14. CMS. CMS quality measure development plan : supporting the transition to the quality payment program 2017 annual report centers for Medicare & Medicaid services (CMS). 2017. https://www.cms.gov/medicare/quality-initiatives-patient-assessment-instruments/value-based-programs/macra-mips-and-apms/2017-cms-mdp-annual-report.pdf.
Google Scholar15. McGoon, MD, Ferrari, P, Armstrong, I, et al. The importance of patient perspectives in pulmonary hypertension. Eur Respir J 2019; 53: 1801919.
Google Scholar | Crossref | Medline16. Wilson, M, Keeley, J, Kingman, M, Wang, J, et al. Current clinical utilization of risk assessment tools in pulmonary arterial hypertension: a descriptive survey of facilitation strategies, patterns, and barriers to use in the United States. Pulmon Circ 2020; 10: 2045894020950186.
Google Scholar | SAGE Journals | ISI